Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Dr Ian Hudson elected vice chair of CHMP

Will serve a three-year term on EMA's scientific advisory committee

- PMLiVE

Novo Nordisk files new haemophilia drug in EU, US

Seeks approval for turoctocog alfa shortly after vatreptacog alfa pulled

European orphan drug applications up 30 per cent

But lower than expected generics applications see EMA reduce new marketing authorisation forecast

Novartis building

Gilenya cuts early relapse, brain loss in MS patients

Boosts prospects for oral drug as competitors emerge

- PMLiVE

Novartis launches YouTube cancer talk show

Each Voice Counts forms part of firm’s existing advanced breast cancer initiative

EU flag

European pharmacovigilance changes approved

European Council formally approves new drug safety legislation

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

- PMLiVE

Ruder Finn launches a social media meningitis campaign

The awareness campaign involves collaboration with three UK meningitis charities

Novartis’ COPD drug Seebri cleared in EU and Japan

Used with Breezhaler device in Europe and inhalation capsule in Japan

Novartis’ Peter Maag appointed president and CEO of XDx

Joins following launch of AlloMap test for transplant patients

Board member Engelbert Tjeenk Willink to leave Boehringer

Replaced by head of established markets Allan Hillgrove

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links